Referencias
Artículos principales
National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Aug 2004 [internet publication].Texto completo
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Texto completo Resumen
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo Resumen
Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020 May;36(5):596-624.Texto completo Resumen
Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo Resumen
Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Texto completo Resumen
Artículos de referencia
1. National Heart, Lung, and Blood Institute. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Aug 2004 [internet publication].Texto completo
2. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-104.Texto completo Resumen
3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo Resumen
4. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998 Jun 13;351(9118):1755-62. Resumen
5. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Jun 21.Texto completo Resumen
6. World Health Organization. Guideline for the pharmacological treatment of hypertension in adults. Aug 2021 [internet publication].Texto completo
7. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 Sep 11;398(10304):957-80.Texto completo Resumen
8. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-913.Texto completo Resumen
9. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002 Feb 27;287(8):1003-10.Texto completo Resumen
10. Abdalla M, Bolen SD, Brettler J, et al. Implementation strategies to improve blood pressure control in the United States: a scientific statement from the American Heart Association and American Medical Association. Hypertension. 2023 Oct;80(10):e143-57.Texto completo Resumen
11. Public Health England. Health matters: combating high blood pressure. Jan 2017 [internet publication].Texto completo
12. Coggon DI, Martyn CN. Time and chance: the stochastic nature of disease causation. Lancet. 2005 Apr 16-22;365(9468):1434-7. Resumen
13. Andersson OK, Beckman-Suurkula M, Sannerstedt R, et al. Does hyperkinetic circulation constitute a pre-hypertensive state? J Intern Med. 1989 Dec;226(6):401-8. Resumen
14. Morimoto A, Uzu T, Fujii T, et al. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997 Dec 13;350(9093):1734-7. Resumen
15. Weinberger MH. More on the sodium saga. Hypertension. 2004 Nov;44(5):609-11.Texto completo Resumen
16. Brenner BM, Garcia DL, Anderson S. Glomeruli and blood pressure: less of one, more the other? Am J Hypertens. 1988 Oct;1(4 Pt 1):335-47. Resumen
17. Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int. 1996 Jun;49(6):1748-53.Texto completo Resumen
18. Cowley AW Jr, Roman RJ. The role of the kidney in hypertension. JAMA. 1996 May 22-29;275(20):1581-9. Resumen
19. Laragh JH. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001 Jan;14(1):84-9. Resumen
20. Fuchs S, Frenzel K, Xiao HD, et al. Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. Curr Hypertens Rep. 2004 Apr;6(2):124-8. Resumen
21. Grassi G, Mancia G. Neurogenic hypertension: is the enigma of its origin near its solution? Hypertension. 2004 Feb;43(2):154-5.Texto completo Resumen
22. Schriffin EL. Remodeling of resistance arteries in essential hypertension and the effects of antihypertensive treatment. Am J Hypertens. 2004 Dec;17(12 Pt 1):1192-200.Texto completo Resumen
23. Rossi R, Chiurlia E, Nuzzo A, et al. Flow-mediated vasodilation and the risk of developing hypertension in healthy post-menopausal women. J Am Coll Cardiol. 2004 Oct 19;44(8):1636-40.Texto completo Resumen
24. Russo C, Oliveri O, Girelli D, et al. Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension. Hypertension. 1997 Apr;29(4):1058-63.Texto completo Resumen
25. Saad MF, Rewers M, Selby J, et al. Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension. 2004 Jun;43(6):1324-31.Texto completo Resumen
26. Castro L, Brant L, Diniz MF, et al. Association of hypertension and insulin resistance in individuals free of diabetes in the ELSA-Brasil cohort. Sci Rep. 2023 Jun 10;13(1):9456.Texto completo Resumen
27. Quesada O, Claggett B, Rodriguez F, et al. Associations of insulin resistance with systolic and diastolic blood pressure: a study from the HCHS/SOL. Hypertension. 2021 Sep;78(3):716-25.Texto completo Resumen
28. Renna NF, de Las Heras N, Miatello RM. Pathophysiology of vascular remodeling in hypertension. Int J Hypertens. 2013;2013:808353.Texto completo Resumen
29. Faxon DP, Creager MA, Smith SC Jr, et al. Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004 Jun 1;109(21):2595-604.Texto completo Resumen
30. Vasan RS, Larson MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med. 2001 Nov 1;345(18):1291-7.Texto completo Resumen
31. Huang Z, Willet WC, Manson JE, et al. Bodyweight, weight change and risk of hypertension in women. Ann Intern Med. 1998 Jan 15;128(2):81-8. Resumen
32. Kannel WB, Garrison RJ, Dannenberg AL. Secular blood pressure trends in normotensive patients. Am Heart J. 1993 Apr;125(4):1154-8. Resumen
33. Jayedi A, Rashidy-Pour A, Khorshidi M, et al. Body mass index, abdominal adiposity, weight gain and risk of developing hypertension: a systematic review and dose-response meta-analysis of more than 2.3 million participants. Obes Rev. 2018 Jan 15;19(5):654-67. Resumen
34. Li W, Fang W, Huang Z, et al. Association between age at onset of overweight and risk of hypertension across adulthood. Heart. 2022 May;108(9):683-8.Texto completo Resumen
35. Sharma AM, Engeli S, Pischon T. New developments in mechanisms of obesity-induced hypertension: role of adipose tissue. Curr Hypertens Rep. 2001 Apr;3(2):152-6. Resumen
36. Heneghan HM, Meron-Eldar S, Brethauer SA, et al. Effect of bariatric surgery on cardiovascular risk profile. Am J Cardiol. 2011 Nov 15;108(10):1499-507. Resumen
37. Sarkhosh K, Birch DW, Shi X, et al. The impact of sleeve gastrectomy on hypertension: a systematic review. Obes Surg. 2012 May;22(5):832-7. Resumen
38. Schiavon CA, Bhatt DL, Ikeoka D, et al. Three-year outcomes of bariatric surgery in patients with obesity and hypertension: a randomized clinical trial. Ann Intern Med. 2020 Nov 3;173(9):685-93. Resumen
39. Blair SN, Goodyear NN, Gibbons LW, et al. Physical fitness and incidence of hypertension in healthy normotensive men and women. JAMA. 1984 Jul 27;252(4):487-90. Resumen
40. Thadhani R, Camargo CA, Stampfer MJ, et al. Prospective study of moderate alcohol consumption and risk of hypertension in young women. Arch Intern Med. 2002 Mar 11;162(5):569-74.Texto completo Resumen
41. Tasnim S, Tang C, Musini VM, et al. Effect of alcohol on blood pressure. Cochrane Database Syst Rev. 2020 Jul 1;(7):CD012787.Texto completo Resumen
42. Di Federico S, Filippini T, Whelton PK, et al. Alcohol intake and blood pressure levels: a dose-response meta-analysis of nonexperimental cohort studies. Hypertension. 2023 Oct;80(10):1961-69.Texto completo Resumen
43. Ding J, Visser M, Kritschevsky SB, et al. The association of regional fat depots with hypertension in older persons of white and African American ethnicity. Am J Hypertens. 2004 Oct;17(10):971-6.Texto completo Resumen
44. Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association. Circulation. 2023 Nov 14;148(20):1636-64.Texto completo Resumen
45. Bjornholt JV, Erikssen G, Kjeldsen SE, et al. Fasting blood glucose is independently associated with resting and exercising blood pressures and development of elevated blood pressures. J Hypertens. 2003 Jul;21(7):1383-9. Resumen
46. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-67.Texto completo Resumen
47. Xia W, Huang Y, Peng B, et al. Relationship between obstructive sleep apnoea syndrome and essential hypertension: a dose-response meta-analysis. Sleep Med. 2018 Jul;47:11-18. Resumen
48. Hou H, Zhao Y, Yu W, et al. Association of obstructive sleep apnea with hypertension: a systematic review and meta-analysis. J Glob Health. 2018 Jun;8(1):010405.Texto completo Resumen
49. Huang L, Trieu K, Yoshimura S, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials. BMJ. 2020 Feb 24;368:m315.Texto completo Resumen
50. Filippini T, Malavolti M, Whelton PK, et al. Blood pressure effects of sodium reduction: dose-response meta-analysis of experimental studies. Circulation. 2021 Apr 20;143(16):1542-67.Texto completo Resumen
51. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001 Jan 4;344(1):3-10.Texto completo Resumen
52. Bondonno CP, Dalgaard F, Blekkenhorst LC, et al. Vegetable nitrate intake, blood pressure and incident cardiovascular disease: Danish Diet, Cancer, and Health Study. Eur J Epidemiol. 2021 Aug;36(8):813-25.Texto completo Resumen
53. Barone Gibbs B, Hivert MF, Jerome GJ, et al. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how?: a scientific statement from the American Heart Association. Hypertension. 2021 Aug;78(2):e26-37.Texto completo Resumen
54. Lichtenstein AH, Appel LJ, Vadiveloo M, et al. 2021 dietary guidance to improve cardiovascular health: a scientific statement from the American Heart Association. Circulation. 2021 Dec 7;144(23):e472-87.Texto completo Resumen
55. US Department of Agriculture; US Department of Health and Human Services. Dietary guidelines for Americans, 2020-2025. 9th ed. Dec 2020 [internet publication].Texto completo
56. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood pressure. Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004937.Texto completo Resumen
57. Yin X, Rodgers A, Perkovic A, et al. Effects of salt substitutes on clinical outcomes: a systematic review and meta-analysis. Heart. 2022 Sep 26;108(20):1608-15. Resumen
58. Tsai YC, Tsao YP, Huang CJ, et al. Effectiveness of salt substitute on cardiovascular outcomes: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2022 Sep;24(9):1147-60.Texto completo Resumen
59. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: behavioral counseling interventions. Nov 2020 [internet publication].Texto completo
60. US Preventive Services Task Force. Healthy diet and physical activity for cardiovascular disease prevention in adults without cardiovascular disease risk factors: behavioral counseling interventions. Jul 2022 [internet publication].Texto completo
61. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: a scientific statement from the American Heart Association. Hypertension. 2019 May;73(5):e35-66.Texto completo Resumen
62. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021 Jul 1;39(7):1293-302.Texto completo
63. US Preventative Services Task Force. Hypertension in adults: screening. Apr 2021 [internet publication].Texto completo
64. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Nov 2023 [internet publication].Texto completo
65. Cloutier L, Daskalopoulou SS, Padwal RS, et al. A new algorithm for the diagnosis of hypertension in Canada. Can J Cardiol. 2015 May;31(5):620-30.Texto completo Resumen
66. Myers MG. A short history of automated office blood pressure - 15 years to SPRINT. J Clin Hypertens (Greenwich). 2016 Aug;18(8):721-4.Texto completo Resumen
67. Roerecke M, Kaczorowski J, Myers MG. Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: a systematic review and meta-analysis. JAMA Intern Med. 2019 Mar 1;179(3):351-62.Texto completo Resumen
68. Cuspidi C. Cardio-renal organ damage and cardiovascular outcomes in hypertension. J Hypertens. 2009 Apr;27(4):702-6.Texto completo Resumen
69. Milani RV, Lavie CJ, Mehra MR, et al. Left ventricular geometry and survival in patients with normal left ventricular ejection fraction. Am J Cardiol. 2006 Apr 1;97(7):959-63. Resumen
70. Yasuno S, Ueshima K, Oba K, et al. Clinical significance of left ventricular hypertrophy and changes in left ventricular mass in high-risk hypertensive patients: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan trial. J Hypertens. 2009 Aug;27(8):1705-12. Resumen
71. Zanchetti A, Hennig M, Hollweck R, et al. Baseline values but not treatment induced changes in carotid intima media thickness predict incident cardiovascular events in treated hypertensives: findings in the European Lacidipine Study on Atherosclerosis (ELSA). Circulation. 2009 Sep 22;120(12):1084-90.Texto completo Resumen
72. Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016 May;101(5):1889-916.Texto completo Resumen
73. Rabi DM, McBrien KA, Sapir-Pichhadze R, et al. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020 May;36(5):596-624.Texto completo Resumen
74. Dobbin SJH, Cameron AC, Petrie MC, et al. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart. 2018 Dec;104(24):1995-2002.Texto completo Resumen
75. MacIntyre IM, Turtle EJ, Farrah TE, et al. Regular acetaminophen use and blood pressure in people with hypertension: the PATH-BP Trial. Circulation. 2022 Feb 8;145(6):416-23.Texto completo Resumen
76. Musini VM, Tejani AM, Bassett K, et al. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database Syst Rev. 2019 Jun 5;(6):CD000028.Texto completo Resumen
77. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016 Jan 30;387(10017):435-43. Resumen
78. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo Resumen
79. Lewis CE, Fine LJ, Beddhu S, et al; SPRINT Research Group. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021 May 20;384(20):1921-30.Texto completo Resumen
80. Vaduganathan M, Claggett BL, Juraschek SP, et al. Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol. 2020 May 1;5(5):576-81.Texto completo Resumen
81. Lonn EM, Bosch J, López-Jaramillo P, et al; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016 May 26;374(21):2009-20.Texto completo Resumen
82. Bosch J, Lonn EM, Jung H, et al. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. Eur Heart J. 2021 Aug 17;42(31):2995-3007.Texto completo Resumen
83. Zhang W, Zhang S, Deng Y, et al; STEP Study Group. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021 Sep 30;385(14):1268-79.Texto completo Resumen
84. Jaeger BC, Bress AP, Bundy JD, et al. Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022 Nov 1;7(11):1138-46. Resumen
85. Beckett NS, Peters R, Fletcher AE, et al; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008 May 1;358(18):1887-98.Texto completo Resumen
86. Williamson JD, Supiano MA, Applegate WB, et al; SPRINT Research Group. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years: a randomized clinical trial. JAMA. 2016 Jun 28;315(24):2673-82.Texto completo Resumen
87. Wang Z, Du X, Hua C, et al. The effect of frailty on the efficacy and safety of intensive blood pressure control: a post hoc analysis of the SPRINT trial. Circulation. 2023 Aug 15;148(7):565-74.Texto completo Resumen
88. Benetos A, Rossignol P, Cherubini A, et al. Polypharmacy in the aging patient: management of hypertension in octogenarians. JAMA. 2015 Jul 14;314(2):170-80. Resumen
89. Saiz LC, Gorricho J, Garjón J, et al. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2022 Nov 18;11(11):CD010315.Texto completo Resumen
90. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.Texto completo Resumen
91. Yang Q, Zheng R, Wang S, et al. Systolic blood pressure control targets to prevent major cardiovascular events and death in patients with type 2 diabetes: a systematic review and network meta-analysis. Hypertension. 2023 Aug;80(8):1640-53. Resumen
92. American Diabetes Association. Standards of care in diabetes - 2024. Diabetes Care. 2024 Jan;47(Suppl_1):S1-321.Texto completo
93. Geleijinse JM, Kork FJ, Grobbee DE. Blood pressure response to changes in sodium and potassium intake: a meta-regression analysis of randomized trials. J Hum Hypertens. 2003 Jul;17(7):471-80. Resumen
94. Whelton SP, Chin A, Xin X, et al. Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med. 2002 Apr 2;136(7):493-503. Resumen
95. Hartley TR, Lovallo WR, Whisett TL, et al. Cardiovascular effects of caffeine in men and women. Am J Cardiol. 2004 Apr 15;93(8):1022-6. Resumen
96. Brand A, Visser ME, Schoonees A, et al. Replacing salt with low-sodium salt substitutes (LSSS) for cardiovascular health in adults, children and pregnant women. Cochrane Database Syst Rev. 2022 Aug 10;(8):CD015207.Texto completo Resumen
97. Neal B, Wu Y, Feng X, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021 Sep 16;385(12):1067-77.Texto completo Resumen
98. Hall ME, Cohen JB, Ard JD, et al; American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021 Nov;78(5):e38-50.Texto completo Resumen
99. Mancia G, Kjeldsen SE, Kreutz R, et al. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension guidelines. Hypertension. 2022 Jun;79(6):1153-66.Texto completo Resumen
100. Gradman AH, Basile JN, Carter BL, et al; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb;4(1):42-50. Resumen
101. Savage RD, Visentin JD, Bronskill SE, et al. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med. 2020 May 1;180(5):643-51.Texto completo Resumen
102. Ishani A, Cushman WC, Leatherman SM, et al; Diuretic Comparison Project Writing Group. Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events. N Engl J Med. 2022 Dec 29;387(26):2401-10. Resumen
103. Jones DW, Whelton PK, Allen N, et al. Management of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap: a scientific statement from the American Heart Association. Hypertension. 2021 Jun;77(6):e58-67.Texto completo Resumen
104. Salam A, Kanukula R, Atkins E, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 Sep;37(9):1768-74. Resumen
105. Bangalore S, Fakheri R, Toklu B, et al. Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ. 2016 Feb 11;352:i438.Texto completo Resumen
106. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019 Nov 16;394(10211):1816-26. Resumen
107. Wright JM, Musini VM, Gill R. First-line drugs for hypertension. Cochrane Database Syst Rev. 2018 Apr 18;(4):CD001841.Texto completo Resumen
108. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981-97.Texto completo Resumen
109. Leenen FH, Nwachuku CE, Black HR, et al; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension. 2006 Sep;48(3):374-84.Texto completo Resumen
110. Thurman JM, Schrier RW. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med. 2003 May;114(7):588-98. Resumen
111. Brown E, Heerspink HJL, Cuthbertson DJ, et al. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021 Jul 17;398(10296):262-76. Resumen
112. Tikkanen I, Narko K, Zeller C, et al; EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015 Mar;38(3):420-8.Texto completo Resumen
113. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.Texto completo Resumen
114. Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014 Dec;16(12):875-82.Texto completo Resumen
115. Cefalu WT, Leiter LA, de Bruin TW, et al. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care. 2015 Jul;38(7):1218-27.Texto completo Resumen
116. Pfeifer M, Townsend RR, Davies MJ, et al. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017 Feb 27;16(1):29.Texto completo Resumen
117. Ferdinand KC, Izzo JL, Lee J, et al. Antihyperglycemic and blood pressure effects of empagliflozin in black patients with type 2 diabetes mellitus and hypertension. Circulation. 2019 Apr 30;139(18):2098-109.Texto completo Resumen
118. Kario K, Ferdinand KC, O'Keefe JH. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease. Prog Cardiovasc Dis. 2020 May-Jun;63(3):249-62.Texto completo Resumen
119. Zhao X, Huang K, Zheng M, et al. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMC Endocr Disord. 2019 Jan 7;19(1):4.Texto completo Resumen
120. Andersen A, Knop FK, Vilsbøll T. A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes. Drugs. 2021 Jun;81(9):1003-30.Texto completo Resumen
121. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. Circulation. 2023 Aug 29;148(9):e9-119.Texto completo Resumen
122. Yusuf S, Sleight P, Pogue J, et al; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000 Jan 20;342(3):145-53.Texto completo Resumen
123. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003 Sep 6;362(9386):782-8. Resumen
124. Braunwald E, Domanski MJ, Fowler SE, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004 Nov 11;351(20):2058-68.Texto completo Resumen
125. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Texto completo Resumen
126. McDonagh TA, Metra M, Adamo M, et al; ESC Scientific Document Group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-726.Texto completo Resumen
127. Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Apr;27(4):387-413.Texto completo Resumen
128. Kittleson MM, Panjrath GS, Amancherla K, et al. 2023 ACC Expert Consensus Decision Pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023 May 9;81(18):1835-78.Texto completo
129. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Texto completo
130. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet. 2002 Sep 7;360(9335):752-60. Resumen
131. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021 Mar;99(3s):S1-87.Texto completo Resumen
132. Qiao Y, Shin JI, Chen TK, et al. Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med. 2020 May 1;180(5):718-26.Texto completo Resumen
133. Agarwal R, Sinha AD, Cramer AE, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021 Dec 30;385(27):2507-19.Texto completo Resumen
134. Agarwal R, Sinha AD, Tu W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease. Circulation. 2022 Aug 30;146(9):718-20.Texto completo Resumen
135. Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun;65(6):1991-2002.Texto completo Resumen
136. Navaneethan SD, Nigwekar SU, Sehgal AR, et al. Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009 Mar;4(3):542-51.Texto completo Resumen
137. Alexandrou ME, Papagianni A, Tsapas A, et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019 Dec;37(12):2307-24. Resumen
138. Nagata D, Hishida E, Masuda T. Practical strategy for treating chronic kidney disease (CKD) - associated with hypertension. Int J Nephrol Renovasc Dis. 2020;13:171-8.Texto completo Resumen
139. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57.Texto completo Resumen
140. Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019 Aug;7(8):606-17. Resumen
141. Herrington WG, Staplin N, Wanner C, et al; EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023 Jan 12;388(2):117-27. Resumen
142. Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023 Feb 1;41(2):295-302.Texto completo Resumen
143. Ruilope LM, Agarwal R, Anker SD, et al. Blood pressure and cardiorenal outcomes with finerenone in chronic kidney disease in type 2 diabetes. Hypertension. 2022 Dec;79(12):2685-95.Texto completo Resumen
144. Yusuf S, Diener HC, Sacco RL, et al; PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008 Sep 18;359(12):1225-37.Texto completo Resumen
145. Yusuf S, Teo K, Anderson C, et al; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008 Sep 27;372(9644):1174-83. Resumen
146. Tveit A, Grundvold I, Olufsen M, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007 Aug 9;120(1):85-91. Resumen
147. Disertori M, Latini R, Barlera S, et al; GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009 Apr 16;360(16):1606-17. [Erratum in: N Engl J Med. 2009 May 28;360(22):2379.]Texto completo Resumen
148. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-156.Texto completo Resumen
149. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. Am J Hypertens. 2004 Sep;17(9):817-22.Texto completo Resumen
150. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized control trial. Lancet. 2004 Sep 4-10;364(9437):849-57. Resumen
151. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov;72(5):e53-90.Texto completo Resumen
152. Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015 Nov 21;386(10008):2059-68.Texto completo Resumen
153. Blumenthal JA, Hinderliter AL, Smith PJ, et al. Effects of lifestyle modification on patients with resistant hypertension: results of the TRIUMPH randomized clinical trial. Circulation. 2021 Oct 12;144(15):1212-26.Texto completo Resumen
154. Lopes S, Mesquita-Bastos J, Garcia C, et al. Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: a randomized clinical trial. JAMA Cardiol. 2021 Nov 1;6(11):1317-23.Texto completo Resumen
155. Charpentier MM, Bundeff A. Treating hypertension in the very elderly. Ann Pharmacother. 2011 Sep;45(9):1138-43. Resumen
156. Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung. 2011;61(4):221-8. Resumen
157. Williamson JD, Pajewski NM, Auchus AP, et al; SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019 Feb 12;321(6):553-61.Texto completo Resumen
158. Gupta A, Perdomo S, Billinger S, et al. Treatment of hypertension reduces cognitive decline in older adults: a systematic review and meta-analysis. BMJ Open. 2020 Nov 17;10(11):e038971.Texto completo Resumen
159. Cunningham EL, Todd SA, Passmore P, et al. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2021 May 24;(5):CD004034.Texto completo Resumen
160. Peters R, Xu Y, Fitzgerald O, et al; Dementia rIsk REduCTion (DIRECT) collaboration. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022 Dec 21;43(48):4980-90.Texto completo Resumen
161. Juraschek SP, Hu JR, Cluett JL, et al. Effects of intensive blood pressure treatment on orthostatic hypotension: a systematic review and individual participant-based meta-analysis. Ann Intern Med. 2021 Jan;174(1):58-68.Texto completo Resumen
162. Blood Pressure Lowering Treatment Trialists' Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021 Sep 18;398(10305):1053-64.Texto completo Resumen
163. Chen T, Shao F, Chen K, et al. Time to clinical benefit of intensive blood pressure lowering in patients 60 years and older with hypertension: a secondary analysis of randomized clinical trials. JAMA Intern Med. 2022 Jun 1;182(6):660-7.Texto completo Resumen
164. Jaffe MG, Lee GA, Young JD, et al. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013 Aug 21;310(7):699-705.Texto completo Resumen
165. Sim JJ, Handler J, Jacobsen SJ, et al. Systematic implementation strategies to improve hypertension: the Kaiser Permanente southern California experience. Can J Cardiol. 2014 May;30(5):544-52. Resumen
166. Shaw KM, Handler J, Wall HK, et al. Improving blood pressure control in a large multiethnic California population through changes in health care delivery 2004-2012. Prev Chronic Dis. 2014 Oct 30;11:E191.Texto completo Resumen
167. Proia KK, Thota AB, Njie GJ, et al. Team-based care and improved blood pressure control: a community guide systematic review. Am J Prev Med. 2014 Jul;47(1):86-99. Resumen
168. Carter BL, Bosworth HB, Green BB. The hypertension team: the role of the pharmacist, nurse, and teamwork in hypertension therapy. J Clin Hypertens (Greenwich). 2012 Jan;14(1):51-65.Texto completo Resumen
169. Cicolini G, Simonetti V, Comparcini D, et al. Efficacy of a nurse-led email reminder program for cardiovascular prevention risk reduction in hypertensive patients: a randomized controlled trial. Int J Nurs Stud. 2014 Jun;51(6):833-43. Resumen
170. McManus RJ, Mant J, Franssen M, et al. Efficacy of self-monitored blood pressure, with or without telemonitoring, for titration of antihypertensive medication (TASMINH4): an unmasked randomised controlled trial. Lancet. 2018 Mar 10;391(10124):949-59.Texto completo Resumen
171. Ayanian JZ, Landon BE, Newhouse JP, et al. Racial and ethnic disparities among enrollees in medicare advantage plans. N Engl J Med. 2014 Dec 11;371(24):2288-97.Texto completo Resumen
172. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet. 2002 Mar 23;359(9311):995-1003. Resumen
173. Ong HT. Beta blockers in hypertension and cardiovascular disease. BMJ. 2007 May 5;334(7600):946-9.Texto completo Resumen
174. Laffin LJ, Rodman D, Luther JM, et al. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension: the target-HTN randomized clinical trial. JAMA. 2023 Sep 26;330(12):1140-50.Texto completo Resumen
175. Hermida RC, Crespo JJ, Domínguez-Sardiña M, et al; Hygia Project Investigators. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020 Dec 21;41(48):4565-76.Texto completo Resumen
176. Mackenzie IS, Rogers A, Poulter NR, et al; TIME Study Group. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022 Oct 22;400(10361):1417-25.Texto completo Resumen
177. Wu C, Zhao P, Xu P, et al. Evening versus morning dosing regimen drug therapy for hypertension. Cochrane Database Syst Rev. 2024 Feb 14;2(2):CD004184. Resumen
178. Bhatt DL, Kandzari DE, O'Neill WW, et al; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10;370(15):1393-401.Texto completo Resumen
179. Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018 Jun 9;391(10137):2346-55. Resumen
180. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018 Jun 0;391(10137):2335-45. Resumen
181. Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study - a randomized controlled trial. J Hypertens. 2016 Sep;34(9):1863-71.Texto completo Resumen
182. Rosa J, Widimský P, Waldauf P, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2015 Feb;67(2):397-403.Texto completo Resumen
183. Fadl Elmula FEM, Feng YM, Jacobs L, et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press. 2017 Aug;26(4):195-203.Texto completo Resumen
184. Azizi M, Schmieder RE, Mahfoud F, et al; RADIANCE-HTN Investigators. Six-month results of treatment-blinded medication titration for hypertension control following randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO Trial. Circulation. 2019 May 28;139(22):2542-53.Texto completo Resumen
185. Böhm M, Kario K, Kandzari DE, et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020 May 2;395(10234):1444-51. Resumen
186. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021 Jun 26;397(10293):2476-86. Resumen
187. Kandzari DE, Townsend RR, Bakris G, et al. Renal denervation in hypertension patients: proceedings from an expert consensus roundtable cosponsored by SCAI and NKF. Catheter Cardiovasc Interv. 2021 Sep;98(3):416-26.Texto completo Resumen
188. Pisano A, Iannone LF, Leo A, et al. Renal denervation for resistant hypertension. Cochrane Database Syst Rev. 2021 Nov 22;(11):CD011499.Texto completo Resumen
189. Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022 Apr 9;399(10333):1401-10. Resumen
190. Bhatt DL, Vaduganathan M, Kandzari DE, et al; SYMPLICITY HTN-3 Steering Committee Investigators. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. Lancet. 2022 Oct 22;400(10361):1405-16. Resumen
191. Azizi M, Mahfoud F, Weber MA, et al; RADIANCE-HTN Investigators. Effects of renal denervation vs sham in resistant hypertension after medication escalation: prespecified analysis at 6 months of the RADIANCE-HTN TRIO randomized clinical trial. JAMA Cardiol. 2022 Dec 1;7(12):1244-52.Texto completo Resumen
192. Azizi M, Saxena M, Wang Y, et al. Endovascular ultrasound renal denervation to treat hypertension: the RADIANCE II randomized clinical trial. JAMA. 2023 Feb 28;329(8):651-61.Texto completo Resumen
193. Kirtane AJ, Sharp ASP, Mahfoud F, et al. Patient-level pooled analysis of ultrasound renal denervation in the sham-controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO trials. JAMA Cardiol. 2023 May 1;8(5):464-73.Texto completo Resumen
194. Ahmad Y, Kane C, Arnold AD, et al. Randomized blinded placebo-controlled trials of renal sympathetic denervation for hypertension: a meta-analysis. Cardiovasc Revasc Med. 2022 Jan;34:112-8.Texto completo Resumen
195. Yang X, Liu H, Chen S, et al. Intravascular renal denervation reduces ambulatory and office blood pressure in patients with essential hypertension: a meta-analysis of randomized sham-controlled trials. Kidney Blood Press Res. 2022;47(6):363-74.Texto completo Resumen
196. Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023 Feb 15 [Epub ahead of print].Texto completo Resumen
197. Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension. 2010 Mar;55(3):619-26.Texto completo Resumen
198. Illig KA, Levy M, Sanchez L, et al. An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial. J Vasc Surg. 2006 Dec;44(6):1213-8. Resumen
199. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010 Oct 5;56(15):1254-8.Texto completo Resumen
200. Bakris GL, Nadim MK, Haller H, et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr;6(2):152-8. Resumen
201. Dong JY, Qin LQ, Zhang Z, et al. Effect of oral L-arginine supplementation on blood pressure: a meta-analysis of randomized, double-blind, placebo-controlled trials. Am Heart J. 2011 Dec;162(6):959-65. Resumen
202. Juraschek SP, Guallar E, Appel LJ, et al. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012 May;95(5):1079-88.Texto completo Resumen
203. Guan Y, Dai P, Wang H. Effects of vitamin C supplementation on essential hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2020 Feb;99(8):e19274.Texto completo Resumen
204. Tamez H, Thadhani RI. Vitamin D and hypertension: an update and review. Curr Opin Nephrol Hypertens. 2012 Sep;21(5):492-9. Resumen
205. Tamez H, Kalim S, Thadhani RI. Does vitamin D modulate blood pressure? Curr Opin Nephrol Hypertens. 2013 Mar;22(2):204-9.Texto completo Resumen
206. Beveridge LA, Struthers AD, Khan F, et al; D-PRESSURE Collaboration. Effect of vitamin D supplementation on blood pressure: a systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med. 2015 May;175(5):745-54.Texto completo Resumen
207. Cormick G, Ciapponi A, Cafferata ML, et al. Calcium supplementation for prevention of primary hypertension. Cochrane Database Syst Rev. 2022 Jan 11;(1):CD010037.Texto completo Resumen
208. Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018 Jun;6(6):464-75.Texto completo Resumen
209. Freeman MW, Halvorsen YD, Marshall W, et al; BrigHTN Investigators. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405. Resumen
210. Schlaich MP, Bellet M, Weber MA, et al; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022 Dec 3;400(10367):1927-37. Resumen
211. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023 Jul 20;389(3):228-38. Resumen
212. Bakris GL, Saxena M, Gupta A, et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024 Mar 5;331(9):740-9. Resumen
213. Flint AC, Conell C, Ren X, et al. Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med. 2019 Jul 18;381(3):243-51.Texto completo Resumen
214. Elfassy T, German CA, Muntner P, et al. Blood pressure and cardiovascular disease mortality among US adults: a sex-stratified analysis, 1999-2019. Hypertension. 2023 Jul;80(7):1452-62. Resumen
215. Cohen JB, Lotito MJ, Trivedi UK, et al. Cardiovascular events and mortality in white coat hypertension: a systematic review and meta-analysis. Ann Intern Med. 2019 Jun 18;170(12):853-62. Resumen
216. Anstey DE, Pugliese D, Abdalla M, et al. An update on masked hypertension. Curr Hypertens Rep. 2017 Oct 25;19(12):94.Texto completo Resumen
217. Nuyujukian DS, Koska J, Bahn G, et al; VADT Investigators. Blood pressure variability and risk of heart failure in ACCORD and the VADT. Diabetes Care. 2020 Jul;43(7):1471-8.Texto completo Resumen
218. Hermida RC, Ayala DE, Mojón A, et al. Sleep-time blood pressure as a therapeutic target for cardiovascular risk reduction in type 2 diabetes. Am J Hypertens. 2012 Mar;25(3):325-34. Resumen
219. Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011 Dec;22(12):2313-21.Texto completo Resumen
220. Hermida RC, Ayala DE, Mojón A, et al. Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. J Am Coll Cardiol. 2011 Sep 6;58(11):1165-73.Texto completo Resumen
221. Hermida RC, Ayala DE, Mojón A, et al. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011 Aug;28(7):601-10. Resumen
222. Hermida RC, Ayala DE, Mojón A, et al. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011 Jun;34(6):1270-6.Texto completo Resumen
223. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. Resumen
224. Zheng Y, Gao X, Jia HY, et al. Influence of hypertension duration and blood pressure levels on cardiovascular disease and all-cause mortality: a large prospective cohort study. Front Cardiovasc Med. 2022 Oct 17;9:948707.Texto completo Resumen
225. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001 Sep 29;358(9287):1033-41. Resumen
226. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996 May 22-29;275(20):1557-62. Resumen
227. Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000 Feb 16;283(7):897-903.Texto completo Resumen
228. Prisant LM, Nalamolu VR. Aortic dissection. J Clin Hypertens (Greenwich). 2005 Jun;7(6):367-71.Texto completo Resumen
229. Schmieder RE, Messerli FH. Hypertension and the heart. J Hum Hypertens. 2000 Oct-Nov;14(10-11):597-604. Resumen
230. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001 Mar;141(3):334-41. Resumen
231. Devereux RB, Roman MJ, Ganau A, et al. Cardiac and arterial hypertrophy and atherosclerosis in hypertension. Hypertension. 1994 Jun;23(6 Pt 1):802-9. Resumen
232. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004 Nov;44(5):595-601.Texto completo Resumen
233. Marcantoni C, Ma LJ, Federspiel C, et al. Hypertensive nephrosclerosis in African Americans versus Caucasians. Kidney Int. 2002 Jul;62(1):172-80.Texto completo Resumen
234. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001 Aug 16;345(7):479-86.Texto completo Resumen
235. Juraschek SP, Cortez MM, Flack JM, et al. Orthostatic hypotension in adults with hypertension: a scientific statement from the American Heart Association. Hypertension. 2024 Mar;81(3):e16-30.Texto completo Resumen
236. Poulsen PL, Ebbehoj E, Hansen KW, et al. Effects of smoking on 24-h ambulatory blood pressure and autonomic function in normoalbuminuric insulin-dependent diabetes mellitus patients. Am J Hypertens. 1998 Sep;11(9):1093-9. Resumen
237. Stamler J, Caggiula AW, Gandits GA. Relation of body mass and alcohol, nutrient, fiber, and caffeine intakes to blood pressure in the special intervention and usual care groups in the Multiple Risk Factor Intervention Trial. Am J Clin Nutr. 1997 Jan;65(1 Suppl):338S-65S. Resumen
238. Choudhry NK, Kronish IM, Vongpatanasin W, et al. Medication adherence and blood pressure control: a scientific statement from the American Heart Association. Hypertension. 2022 Jan;79(1):e1-14.Texto completo Resumen
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad